{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:49:47Z","timestamp":1787849387849,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s13318-021-00672-6","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T10:02:57Z","timestamp":1613988177000},"page":"325-342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review"],"prefix":"10.1007","volume":"46","author":[{"given":"Mariam","family":"Abdel Jalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervat","family":"Alsous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khawla","family":"Abu-Hammour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"issue":"12","key":"672_CR1","doi-asserted-by":"crossref","first-page":"E67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin EJ, et al. Heart disease and stroke statistics\u20142018 update: a report from the American Heart Association. Circulation. 2018;137(12):E67\u2013492.","journal-title":"Circulation"},{"issue":"5","key":"672_CR2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.4070\/kcj.2017.0040","volume":"47","author":"SA Batul","year":"2017","unstructured":"Batul SA, Gopinathannair R. Atrial fibrillation in heart failure: a therapeutic challenge of our times. Korean Circ J. 2017;47(5):644\u201362.","journal-title":"Korean Circ J."},{"issue":"10","key":"672_CR3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.amjmed.2019.04.022","volume":"132","author":"S Angraal","year":"2019","unstructured":"Angraal S, et al. Digoxin use and associated adverse events among older adults. Am J Med. 2019;132(10):1191\u20138.","journal-title":"Am J Med"},{"issue":"8","key":"672_CR4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","volume":"336","author":"R Garg","year":"1997","unstructured":"Garg R, Gorlin R, Smith T, Yusuf S. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"672_CR5","first-page":"13","volume":"95","author":"WE Chavey","year":"2017","unstructured":"Chavey WE, Hogikyan RV, Harrison RV, Nicklas JM. Heart failure due to reduced ejection fraction: medical management. Am Fam Physician. 2017;95(1):13\u201320.","journal-title":"Am Fam Physician"},{"issue":"27","key":"672_CR6","first-page":"2095","volume":"38","author":"U Bavendiek","year":"2017","unstructured":"Bavendiek U, Aguirre Davila L, Koch A, Bauersachs J. Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J. 2017;38(27):2095\u20139.","journal-title":"Eur Heart J"},{"issue":"5","key":"672_CR7","first-page":"363","volume":"105","author":"G Karthikeyan","year":"2019","unstructured":"Karthikeyan G, et al. Digoxin and clinical outcomes in the Global Rheumatic Heart Disease Registry. Heart. 2019;105(5):363\u20139.","journal-title":"Heart"},{"issue":"1","key":"672_CR8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.31086\/tjgeri.2020.144","volume":"23","author":"\u0130 Yilmaz","year":"2020","unstructured":"Yilmaz \u0130, Bilgili S, Bozkaya G. Evaluation of digoxin levels in elderly patients in a training hospital: an 11-year follow-up. Turk Geriatr Derg. 2020;23(1):108\u201317.","journal-title":"Turk Geriatr Derg"},{"key":"672_CR9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejim.2019.04.024","volume":"67","author":"ERFL de Moraes","year":"2019","unstructured":"de Moraes ERFL, et al. Prevalence of atrial fibrillation and stroke risk assessment based on telemedicine screening tools in a primary healthcare setting. Eur J Intern Med. 2019;67:36\u201341.","journal-title":"Eur J Intern Med"},{"issue":"5","key":"672_CR10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00002512-200017050-00003","volume":"17","author":"CG Hanratty","year":"2000","unstructured":"Hanratty CG, McGlinchey P, Johnston GD, Passmore AP. Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging. 2000;17(5):353\u201362.","journal-title":"Drugs Aging"},{"issue":"5","key":"672_CR11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.amjopharm.2010.10.001","volume":"8","author":"JWM Cheng","year":"2010","unstructured":"Cheng JWM, Rybak I. Use of digoxin for heart failure and atrial fibrillation in elderly patients. Am J Geriatr Pharmacother. 2010;8(5):419\u201327.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"7","key":"672_CR12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/bcp.14272","volume":"86","author":"MH Abdel Jalil","year":"2020","unstructured":"Abdel Jalil MH, Abdullah N, Alsous MM, Saleh M, Abu-Hammour K. A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population. Br J Clin Pharmacol. 2020;86(7):1267\u201380.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"672_CR13","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","volume":"54","author":"S Kanji","year":"2015","unstructured":"Kanji S, et al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet. 2015;54(7):783\u201395.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"672_CR14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00003088-200746030-00003","volume":"46","author":"K Brendel","year":"2007","unstructured":"Brendel K, et al. Are population pharmacokinetic and\/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet. 2007;46(3):221\u201334.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"672_CR15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2165\/11594230-000000000-00000","volume":"28","author":"M Yukawa","year":"2011","unstructured":"Yukawa M, et al. Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy. Drugs Aging. 2011;28(10):831\u201341.","journal-title":"Drugs Aging"},{"issue":"2","key":"672_CR16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s13318-012-0107-8","volume":"38","author":"R Chen","year":"2012","unstructured":"Chen R, Wang SZM. Population pharmacokinetics of digoxin in elderly patients. Eur J Drug Metab Pharmacokinet. 2012;38(2):115\u201321.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"672_CR17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40780-015-0023-6","volume":"1","author":"T Komatsu","year":"2015","unstructured":"Komatsu T, et al. Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients. J Pharm Heal Care Sci. 2015;1(1):25.","journal-title":"J Pharm Heal Care Sci"},{"issue":"9","key":"672_CR18","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.clinthera.2020.07.011","volume":"42","author":"P Du","year":"2020","unstructured":"Du P, et al. Impact of SLCO4C1 genotypes, creatinine, and spironolactone on digoxin population pharmacokinetic variables in patients with cardiac insufficiency. Clin Ther. 2020;42(9):1799-1810.e3.","journal-title":"Clin Ther"},{"issue":"2","key":"672_CR19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/j.1552-4604.1997.tb04766.x","volume":"37","author":"E Yukawa","year":"1997","unstructured":"Yukawa E, Honda T, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. J Clin Pharmacol. 1997;37(2):92\u2013100.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"672_CR20","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00228-002-0553-3","volume":"58","author":"B Hornestam","year":"2003","unstructured":"Hornestam B, Jerling M, Karlsson MO, Held P, DAAf Trial Group. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic pharmacodynamic analysis based on the Digitalis in acute atrial fibrillation trial. Eur J Clin Pharmacol. 2003;58(11):747\u201355.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"672_CR21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/j.1552-4604.1996.tb04196.x","volume":"36","author":"LD Carlton","year":"1996","unstructured":"Carlton LD, Patterson JH, Mattson CN, Schmith VD. The effects of epoprostenol on drug disposition I: a pilot study of the pharmacokinetics of digoxin with and without epoprostenol in patients with congestive heart failure. J Clin Pharmacol. 1996;36(3):257\u201364.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"672_CR22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2165\/00003088-199222010-00006","volume":"22","author":"PJ Williams","year":"1992","unstructured":"Williams PJ, Lane J, Murray W, Mergener MA, Kamigaki M. Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling. Clin Pharmacokinet. 1992;22(1):66\u201374.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"672_CR23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/bdd.306","volume":"23","author":"F Suematsu","year":"2002","unstructured":"Suematsu F, et al. Pharmacoepidemiologic detection of calcium channel blocker-induced change on digoxin clearance using multiple trough screen analysis. Biopharm Drug Dispos. 2002;23(5):173\u201381.","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"672_CR24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.clinthera.2014.01.019","volume":"36","author":"SA Choi","year":"2014","unstructured":"Choi SA, Yun HY, Lee ES, Shin WG. A population pharmacokinetic analysis of the influence of nutritional status of digoxin in hospitalized Korean patients. Clin Ther. 2014;36(3):389\u2013400.","journal-title":"Clin Ther"},{"issue":"6","key":"672_CR25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/aps.2010.51","volume":"31","author":"X Zhou","year":"2010","unstructured":"Zhou X, Gao Y, Guan Z, Li Z, Li J. Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. Acta Pharmacol Sin. 2010;31(6):753\u20138.","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"672_CR26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2165\/00003088-200140100-00005","volume":"40","author":"E Yukawa","year":"2001","unstructured":"Yukawa E, et al. Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. Clin Pharmacokinet. 2001;40(10):773\u201381.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"672_CR27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5414\/CPP38291","volume":"38","author":"NV Nagaraja","year":"2000","unstructured":"Nagaraja NV, Park YJ, Jeon S, Sands CD, Derendorf H. Population pharmacokinetics of digoxin in Korean patients. Int J Clin Pharmacol Ther. 2000;38(6):291\u20137.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"672_CR28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-199602000-00008","volume":"18","author":"LA Bauer","year":"1996","unstructured":"Bauer LA, Horn JR, Pettit H. Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations. Ther Drug Monit. 1996;18(1):46\u201352.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"672_CR29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01061728","volume":"5","author":"LB Sheiner","year":"1977","unstructured":"Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977;5(5):445\u201379.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"9","key":"672_CR30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.2042-7158.1992.tb05515.x","volume":"44","author":"E Yukawa","year":"1992","unstructured":"Yukawa E, Mine H, Higuchi S, Aoyama T. Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol. 1992;44(9):761\u20135.","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"672_CR31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehi687","volume":"27","author":"A Ahmed","year":"2006","unstructured":"Ahmed A, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27(2):178\u201386.","journal-title":"Eur Heart J"},{"issue":"9","key":"672_CR32","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.hrthm.2014.06.007","volume":"11","author":"BA Mulder","year":"2014","unstructured":"Mulder BA, et al. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Hear Rhythm. 2014;11(9):1543\u201350.","journal-title":"Hear Rhythm"},{"issue":"7","key":"672_CR33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jacc.2014.03.060","volume":"64","author":"MP Turakhia","year":"2014","unstructured":"Turakhia MP, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64(7):660\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"672_CR34","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1161\/CIRCULATIONAHA.114.013709","volume":"132","author":"T-F Chao","year":"2015","unstructured":"Chao T-F, et al. Rate-control treatment and mortality in atrial fibrillation. Circulation. 2015;132(17):1604\u201312.","journal-title":"Circulation"},{"issue":"20","key":"672_CR35","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/eurheartj\/ehs348","volume":"34","author":"MG Whitbeck","year":"2013","unstructured":"Whitbeck MG, et al. Increased mortality among patients taking digoxin\u2014analysis from the AFFIRM study. Eur Heart J. 2013;34(20):1481\u20138.","journal-title":"Eur Heart J"},{"issue":"20","key":"672_CR36","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/eurheartj\/eht120","volume":"34","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade M, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34(20):1489\u201397.","journal-title":"Eur Heart J"},{"issue":"9985","key":"672_CR37","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/S0140-6736(14)61836-5","volume":"385","author":"JB Washam","year":"2015","unstructured":"Washam JB, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Lancet. 2015;385(9985):2363\u201370.","journal-title":"Lancet"},{"issue":"5","key":"672_CR38","first-page":"391","volume":"70","author":"RJ DiDomenico","year":"2017","unstructured":"DiDomenico RJ. Should digoxin continue to be used for the management of atrial fibrillation? Can J Hosp Pharm. 2017;70(5):391\u20134.","journal-title":"Can J Hosp Pharm"},{"issue":"2","key":"672_CR39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40262-016-0428-x","volume":"56","author":"A Marsot","year":"2017","unstructured":"Marsot A, Guilhaumou R, Riff C, Blin O. Amikacin in critically ill patients: a review of population pharmacokinetic studies. Clin Pharmacokinet. 2017;56(2):127\u201338.","journal-title":"Clin. Pharmacokinet."},{"key":"672_CR40","volume-title":"Applied clinical pharmacokinetics","author":"L Bauer","year":"2008","unstructured":"Bauer L. Applied clinical pharmacokinetics. 3rd ed. New York: McGraw Hill; 2008.","edition":"3"},{"issue":"3","key":"672_CR41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF00543318","volume":"28","author":"MA Naafs","year":"1985","unstructured":"Naafs MA, et al. Decreased renal clearance of digoxin in chronic congestive heart failure. Eur J Clin Pharmacol. 1985;28(3):249\u201352.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"672_CR42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF00542456","volume":"22","author":"KE Pedersen","year":"1982","unstructured":"Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Pedersen KK. The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects. Eur J Clin Pharmacol. 1982;22(2):123\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"672_CR43","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF00314854","volume":"42","author":"A Hedman","year":"1992","unstructured":"Hedman A, Angelin B, Arvidsson A, Dahlqvist R. Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. Eur J Clin Pharmacol. 1992;42(5):481\u20135.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"672_CR44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11897-011-0076-2","volume":"9","author":"JA Talameh","year":"2012","unstructured":"Talameh JA, Lanfear DE. Pharmacogenetics in chronic heart failure: new developments and current challenges. Curr Heart Fail Rep. 2012;9(1):23\u201332.","journal-title":"Curr Heart Fail Rep"},{"issue":"5","key":"672_CR45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/CRD.0000000000000028","volume":"22","author":"A Oni-Orisan","year":"2014","unstructured":"Oni-Orisan A, Lanfear DE. Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev. 2014;22(5):193\u20138.","journal-title":"Cardiol Rev"},{"key":"672_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69326-y","author":"C Hsin","year":"2020","unstructured":"Hsin C, et al. Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-020-69326-y.","journal-title":"Sci Rep"},{"issue":"1","key":"672_CR47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/FTD.0b013e3181fd4c30","volume":"33","author":"A DeFrance","year":"2011","unstructured":"DeFrance A, Armbruster D, Petty D, Cooper KC, Dasgupta A. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone. Ther Drug Monit. 2011;33(1):128\u201331.","journal-title":"Ther Drug Monit"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00672-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-021-00672-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00672-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T20:31:07Z","timestamp":1620073867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-021-00672-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1007\/s13318-021-00672-6","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"assertion":[{"value":"22 February 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to conduct this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts to declare","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Extracted data are presented in the text.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: M.A.J. Conducting the review: M.A.J., N.A., M.A., K.A. Data analysis: M.A.J., N.A., M.A. Writing the manuscript: M.A.J., N.A., M.A., K.A. Reviewing and approving the manuscript: M.A.J., N.A., M.A., K.A.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}